Article
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Leukemia research - 1 Jul 2022
Zhao Davidson, Zarif Mojgan, Eladl Entsar, Capo-Chichi José-Mario, Smith Adam C, Atenafu Eshetu G, Tierens Anne, Minden Mark D, Schuh Andre, Chang Hong
Abstract excerpt
BACKGROUND: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a prognostically diverse disease. Owing to its favourable prognosis, AML-MRC with mutated NPM1 (NPM1MUT) diagnosed on the basis of multi-lineage dysplasia has been reclassified into "AML with mutated NPM1". However, it remains unclear if NPM1MUT AML with antecedent MDS or MDS/MPN (AML-MRC-H) should also be reclassified into this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.